Weighted tax deduction on R&D will be reduced from current 200% to 150% from FY18 and to 100% from FY21. The reduction of benefits on account of R&D was anticipated to kick in from current year (FY17). Although a delay in phasing out is better than anticipated, this is still a long-term negative for the sector.
3,000 medical stores will be opened under Pradhan Mantri Jan Aushadhi Yojana to make generic medicines available. Pharma companies market branded medicines in India and improving access to generic medicines by the government will directly compete against branded players. This is a slight negative for the sector. Higher impact for companies which have large share of primary care and which don’t charge a price premium.
Benefit of section 10AA to new SEZ units will be available to those units which commence activity before FY20. Dr. Reddy’s, Aurobindo, and Divis are setting up new manufacturing facilities in SEZ areas.
Pharmaceuticals – Neutral
|Reduce weighted R&D deduction to 150% from April 2017 and 100% from April 2020||Negative for all pharma companies|
|10% tax rate for global income accrued from patent developed and filed in India||To benefit players like Dr Reddys' which can commercialize patents on global basis|
|Customs duty on import of Molybdenum-99 has been removed||Positive for radio pharma players like Jubilant and Poly Medicure|
|An amount of Rs. 850cr allocated over next few years for several animal wellness programs||Positive for animal health players like SeQuent Scientific and Omkar Speciality|
|Health cover of Rs.1lakh for BPL families with additional Rs.30,000 cover for senior citizens||Positive for healthcare providers like Apollo as it expands coverage market|
Aurobindo Pharma gets USFDA nod for non-aspirin pain reliever
Union Budget set the direction for a balanced growth: Bayer CropScience